SEC Form 4 · accession 0001214659-15-006720
Anthera Pharmaceuticals Inc · ANTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Debra Odink
Officer — Chief Technology Officer
Period of report
Sep 17, 2015
Accepted (ET)
Sep 18, 2015 · 6:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001316175
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $9.48 | Sep 17, 2015 | A | 60,000 | A | — | Sep 17, 2025 | Common stock | 60,000 | 60,000 | D |
| Stock option (right to buy)F2 | $9.48 | Sep 17, 2015 | A | 30,000 | A | — | Sep 17, 2025 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1This stock option vests monthly over four years beginning December 30, 2014 (the Vesting Start Date). The Stock Option is completely vested on the fourth anniversary of the vesting start date and will expire on September 17, 2025.
- F2This stock option vests monthly over four years beginning September 17, 2015 (the Vesting Start Date). The Stock Option is completely vested on the fourth anniversary of the vesting start date and will expire on September 17, 2025.